We are really looking forward to hosting an IRDG members visit to Helsinn Pharmaceuticals Centre of Excellence in Research & Development this November.
Helsinn, a privately owned pharmaceutical company, has established a Centre of Excellence in Research and Development for Oral Solid Dosage (OSD) at its Dublin facility, Helsinn Birex Pharmaceuticals. Helsinn’s core business is the in-licensing of late stage pharmaceutical compounds in therapeutic niche areas for development and subsequent commercial manufacture and distribution. The company is primarily active in oncology supportive care, anti-inflammatory and gastrointestinal treatments. The investment was part of Helsinn’s strategic decision to strengthen its in-house development capabilities. The Helsinn investment has established the Irish operation as the centre of knowledge and learning for OSD products in the Helsinn Group, and the launch site for new products within its portfolio. This investment puts the Irish operation at the core of Helsinn’s R&D activities.
We look forward to sharing more details shortly. Places will be limited.